We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 72,162 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/4/2019 07:24 | Oh deary me. No wonder for the rather odd hughwilson character , who professed huge pharma knowledge, and personal connections in the industry, but who spelt Astrazeneca, *Astra Zenica*. Could they sell this idea to a scammer operating out of west africa? | escapetohome | |
15/4/2019 07:23 | >> tankerton Yes every program I ever worked on had problems and delays. However, the issue here is that the technology is nowhere near as advanced as has been claimed by the company and swallowed lock stock and barrel by yourself. Remember the famous trip to Japan to try to sell the technology? What a complete waste of time that was because the technology was nowhere near a state which was useful to partners. Clearly all those companies saw through that which is why nothing came from the trip. This company is a shambles.....which is maybe not surprising for a small biotech company with limited resources but the problem is your naive understanding of what is going on. It seems to me due to the extended delays and further costs in going back and starting again, it is highly likely a further fund raising will now be required. Expect the forward selling to begin now..... | nobbygnome | |
15/4/2019 07:12 | Uh oh! It looks like they are going back and starting again. It seems like they haven't project managed the CROs and partners effectively. Clearly the technology is not nearly as advanced as the naive investor believes. And back to ovalbumin. You really have to laugh......this technology is light years away from producing anything meaningful. What a shambles! | nobbygnome | |
15/4/2019 07:11 | Hmm great more delays. And they didn't write it down in sufficient detail the first time? What the hell? | dplewis1 | |
14/4/2019 08:28 | Nobbo,So in your 28 years of experience, every trial,every test has gone exactly to plan and produced the required results has it. N4 has had 3 years of unprecedented success with Nuvec. You with your 28 years of experience should know above all people that there is a lot of trial and error in pharma and it is all about working towards the correct result. Your complete failure to understand that discredits your argument. It is clear that you are not an investor so you spending your time here trying to slate the company in my opinion is highly suspect so you will now also be put on filter as I believe that you have nothing constructive or of value to add. | tankerton | |
14/4/2019 07:25 | He struggles with basic concepts like the meaning of sour grapes, so it's quite clearly the same poster as hughwilson even though he keeps denying it. He's still waiting for those hundreds of deals from Japan Nobby - Nigel said so therefore it must be happening! | dplewis1 | |
14/4/2019 07:10 | LOL but who has been right so far. I worked for 28 years in the industry doing exactly the sort of experiments we are talking about. Those warning lights are flashing brightly...... History is repeating itself here. Nigel keeps on saying everything is going fine, you believe him.....and then everything fails! | nobbygnome | |
13/4/2019 22:47 | That sounds like sour grapes talking Nobbo. Constantly saying the same things over and over again does not make it right. Strange thing is that when I repeat your thoughts to someone I know who is high up in life science,their words are that it is you that does not understand. I know whose words I give more weight to and they are not yours. | tankerton | |
13/4/2019 21:06 | >> tankerton The warning lights are flashing red. If you choose to ignore them you are as gullible as we all know you are. That report is naive and is written by someone who doesn't understand science or drug development. That is not surprising because there are few people in the City who have the required knowledge. The time line for any success goes even further out and no doubt a further fund raising will be required in the next year or so as the delays continue. You invest in this company even at this lowly level at your peril.... All IMHO of course... | nobbygnome | |
13/4/2019 18:31 | Tankerton. I stated a few months back I would sell off my investment if the UoA results came back as a fail and irrespective of what some say, I feel this was not a fail. It’s teething issues and these are needed to conclusively produce the data package showing areas that previously had ‘inconsistent& I will continue to hold (at a huge loss) and wait for the retest. | featherby81 | |
13/4/2019 18:12 | featherby81, In the world of pharma and research and development there is no such thing as complete success. Normally there are hurdles that have to be overcome. N4 had up to now, for a period of three years not only met but exceeded expectations on its Nuvec development. The last RNS set out its plans to overcome those problems and continue with its development. In my opinion Myles is correct in calling the share price drop a "huge overreaction". | tankerton | |
13/4/2019 18:01 | Ch1rp. This’ll turn around in time, it’s been a tough week but anyone who claims this is dead couldn’t actually give you a report with as much information as First Equitys recent writeup explaining why it’s dead. Hold for gold :) | featherby81 | |
13/4/2019 14:59 | N4 Report. | tankerton | |
13/4/2019 13:57 | So you are implying you know some inside information. I would be very careful about trading if that is the case... | nobbygnome | |
13/4/2019 13:41 | Fortunately filtered, Nobb:))) | ch1rp | |
13/4/2019 12:47 | Explain to us why. What would justify a market cap of approaching £15 million? They have one technology which they are struggling to make work in vivo. | nobbygnome | |
13/4/2019 11:34 | Sorry, Nobbs:))) | ch1rp | |
13/4/2019 11:34 | Hobbs you don't have to like it but UP is where this share is going. See you all at 15p:))) | ch1rp | |
12/4/2019 18:12 | You said that before it dropped 50%. You're almost as stupid as hughwilson. | dplewis1 | |
12/4/2019 17:30 | This is going UP!!!!! | ch1rp | |
12/4/2019 12:07 | Oh for goodness sake go find some other plac3 to doom monger. I'm fully invested and will see this to £5. GLA Long Term investors and what a perfect opportunity this presents:))) | ch1rp | |
11/4/2019 12:34 | Wrong ken chung. Not even lemmings are touching it. The mushrooms have died. This is a corpse. | escapetohome | |
11/4/2019 12:17 | Do you think he really cares?............ha | thaiflyer1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions